摘要
目的:观察福施乐治疗BPH的有效性和安全性。方法:采用多中心、开放性、自身前后对照的临床研究方法,对60例BPH患者采用福施乐治疗12周。以国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、膀胱残余尿(PVR)和前列腺体积为主要疗效指标,以生活质量评分(QOL)和平均尿流率(Qave)为次要疗效指标,来评价福施乐治疗BPH的效果。结果:治疗12周后,患者IPSS评分、Qmax、PVR、QOL评分、Qave均比治疗前明显改善(P<0.01),而前列腺体积治疗前后无显著性差异(P>0.05)。结论:福施乐可明显改善BPH患者的排尿症状,增加尿流率,减少残余尿,无明显不良反应,治疗BPH安全、有效。
Objective： To observe the efficacy and safety of Fushile, a compound preparation of several Chinese herbal drugs, in the treatment of benign prostatic hyperplasia （BPH）. Methods ： A multi-centered, open and self-controlled clinical trial was performed in 60 BPH patients, who were treated with Fushile for 12 weeks. The efficacy of the compound was evaluated by the International Prostate Syndrome Score （IPSS） , maximum flow rate （Qmax）, post void residual （PVR） and prostate volume as the primary indexes and by the quality of life （QOL） score and average urinary flow rate （Qave） as the secondary indexes. Results： After 12 weeks of Fush- ile treatment, IPSS, Qmax, PVR, QOL and Qave of the BPH patients were significantly improved （ P 〈 0.01 ）, but there was no significant difference in the volume of the prostate before and after the treatment （ P 〉 0.05 ）. No adverse events were observed in any of the patients. Conclusion ： Fushile can significantly improve voiding symptoms, increase urinary flow and reduce PVR in BPH patients. It is effective and safe in the treatment of BPH.
出处
《中华男科学杂志》
CAS
CSCD
2008年第3期227-230,共4页
National Journal of Andrology
关键词
良性前列腺增生
福施乐
疗效
安全性
benign prostatic hyperplasia
Fushile
efficacy
safety
作者简介
商学军（1971-），男，江苏盱眙县人，副主任医师，副教授，医学博士，从事男科学专业。通讯作者：商学军，E-mail：shangxj@androl.cn
